Publications by authors named "Ciska Verbaanderd"

Claim this Profile
B
Biomarker-Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union.
Ciska Verbaanderd, Ana Trullás Jimeno, Jörg Engelbergs, Hilke Zander, Ilona Reischl

Clin Pharmacol Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to balance valuable innovation with affordable access to medicines in Belgium?
Steven Simoens, Khadidja Abdallah, Liese Barbier, Teresa Barcina Lacosta, Alessandra Blonda, Ciska Verbaanderd

Front Pharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.
Jorn Mulder, Robin Verjans, Ciska Verbaanderd, Elias Pean, Just Weemers

Front Med (Lausanne)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research.
Ciska Verbaanderd, Ilse Rooman, Isabelle Huys

Trials· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing drugs in oncology: From candidate selection to clinical adoption.
Pan Pantziarka, Ciska Verbaanderd, Isabelle Huys, Gauthier Bouche, Lydie Meheus

Semin Cancer Biol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective.
Stefanie Broes, Ciska Verbaanderd, Minne Casteels, Denis Lacombe, Isabelle Huys

Front Med (Lausanne)· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biased by design? Clinical trials and patient benefit in oncology.
Pan Pantziarka, Ciska Verbaanderd, Lydie Meheus

Future Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients.
Ciska Verbaanderd, Ilse Rooman, Lydie Meheus, Isabelle Huys

Front Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ReDO_DB: the repurposing drugs in oncology database.
Pan Pantziarka, Ciska Verbaanderd, Vidula Sukhatme, I Rica Capistrano, Sergio Crispino

Ecancermedicalscience· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.
Ciska Verbaanderd, Hannelore Maes, Marco B Schaaf, Vikas P Sukhatme, Pan Pantziarka

Ecancermedicalscience· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing Drugs in Oncology: Next Steps.
Ciska Verbaanderd, Lydie Meheus, Isabelle Huys, Pan Pantziarka

Trends Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropathy of Trigeminal Nerve Branches After Oral and Maxillofacial Treatment.
Jimoh Olubanwo Agbaje, Elke Van de Casteele, Marjolein Hiel, Ciska Verbaanderd, Ivo Lambrichts

J Maxillofac Oral Surg· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis